Canada's MindWalk Q3 revenue rises on US growth

Mindwalk Holdings

12/03/2026 12:41

Overview

Canada Bio-Native AI firm's fiscal Q3 revenue grew 52% yr/yr to C$4.2 mln

Company signed first annual enterprise LensAI platform contract, shifting to recurring revenue

US revenue doubled as company focused strategically on North America

Outlook

MindWalk says LensAI platform rollout is scaling across its client base

Company expects continued focus on North America due to favorable regulatory environment

MindWalk advancing dengue, GLP-1, and influenza programs with upcoming milestones

Result Drivers

NORTH AMERICA FOCUS - Co said US revenue doubled year over year, driven by strategic focus on North America and new biologics operations in Boston and Cambridge

RECURRING REVENUE CONTRACT - Co signed first annual enterprise LensAI platform contract, shifting part of revenue from project-based to contracted and recurring

Company press release: ID:nBw1LlMBza

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
C$4.20 mln
C$4.61 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for MindWalk Holdings Corp is $4.00, about 212.5% above its March 11 closing price of $1.28

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)